secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021712
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study
--------------------------------------------------------------------------------

- Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.
- Deferoxamine (DFO) exhibited limited intracellular activity under equivalent conditions.
- Telomir-1 formulated with zinc (Telomir-Zn) enables controlled exchange of metal ions – binding excess iron/copper while contributing zinc.
- Findings support research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics in aging and disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/0001493152-25-021712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225021712/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer